CN102159249A - 具有低滥用潜在性的聚乙二醇化阿片样物质 - Google Patents

具有低滥用潜在性的聚乙二醇化阿片样物质 Download PDF

Info

Publication number
CN102159249A
CN102159249A CN2009801360891A CN200980136089A CN102159249A CN 102159249 A CN102159249 A CN 102159249A CN 2009801360891 A CN2009801360891 A CN 2009801360891A CN 200980136089 A CN200980136089 A CN 200980136089A CN 102159249 A CN102159249 A CN 102159249A
Authority
CN
China
Prior art keywords
chemical compound
opioid
less
oligomer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801360891A
Other languages
English (en)
Chinese (zh)
Inventor
C·S·诸得-菲斯伯恩
T·A·瑞丽
A·扎卡利斯
H·瓜萨哈尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,395 external-priority patent/US8173666B2/en
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN102159249A publication Critical patent/CN102159249A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801360891A 2008-09-16 2009-09-16 具有低滥用潜在性的聚乙二醇化阿片样物质 Pending CN102159249A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19224708P 2008-09-16 2008-09-16
US61/192,247 2008-09-16
US12/558,395 US8173666B2 (en) 2007-03-12 2009-09-11 Oligomer-opioid agonist conjugates
US12/558,395 2009-09-11
PCT/US2009/005174 WO2010033195A1 (en) 2008-09-16 2009-09-16 Pegylated opioids with low potential for abuse

Publications (1)

Publication Number Publication Date
CN102159249A true CN102159249A (zh) 2011-08-17

Family

ID=41611345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801360891A Pending CN102159249A (zh) 2008-09-16 2009-09-16 具有低滥用潜在性的聚乙二醇化阿片样物质

Country Status (10)

Country Link
US (2) US20110237614A1 (https=)
EP (2) EP3342427A1 (https=)
JP (1) JP5827123B2 (https=)
KR (1) KR101660996B1 (https=)
CN (1) CN102159249A (https=)
AU (1) AU2009292631A1 (https=)
CA (1) CA2734333A1 (https=)
IL (1) IL211762A (https=)
MX (1) MX347741B (https=)
WO (1) WO2010033195A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017129046A1 (zh) * 2016-01-29 2017-08-03 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107033154A (zh) * 2016-02-02 2017-08-11 苏州派格生物科技有限公司 阿片受体拮抗剂缀合物及其应用
WO2018113581A1 (zh) * 2016-12-22 2018-06-28 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
CN111107849A (zh) * 2017-07-20 2020-05-05 苏州润鑫达泰生物医药有限公司 抗滥用长效释放阿片样前药
CN115181109A (zh) * 2021-04-02 2022-10-14 南京正大天晴制药有限公司 吗啡喃衍生物的晶体及其制备方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP2628489B1 (en) * 2009-07-21 2017-03-01 Nektar Therapeutics PEG oligomer-fentanyl conjugates
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
WO2013070617A1 (en) 2011-11-07 2013-05-16 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
EP2895457B1 (en) 2012-09-17 2020-05-20 Nektar Therapeutics Oligomer-containing benzamide-based compounds
LT2914599T (lt) 2012-10-30 2018-02-12 Nektar Therapeutics Alfa-6-mpeg6-hidroksikodono, kaip opioidų agonistų, kieta druskos forma ir jos panaudojimas
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
JP6577943B2 (ja) * 2013-06-28 2019-09-18 ネクター セラピューティクス κオピオイド作動薬及びその使用
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017041095A1 (en) 2015-09-03 2017-03-09 Allegheny-Singer Research Institute Hydrophilic fentanyl derivatives
JP7177392B2 (ja) 2018-03-29 2022-11-24 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2654756A (en) * 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2628962A (en) 1949-10-20 1953-02-17 Mallinckrodt Chemical Works Method for preparing dihydrocodeinone, dihydromorphinone, and codeinone
US2715626A (en) * 1950-07-05 1955-08-16 Merck & Co Inc Process of preparing dihydrocodeinone
US2649454A (en) 1951-08-20 1953-08-18 Univ California Method for preparing dihydromorphinone, dihydrocodeinone, and dihydropseudocodeinone
US2806033A (en) * 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3254088A (en) * 1961-03-14 1966-05-31 Lewenstein Morphine derivative
JPS60149589A (ja) * 1984-01-14 1985-08-07 Daiichi Rajio Isotope Kenkyusho:Kk クラウン化コデイノン類
US5843900A (en) * 1991-04-01 1998-12-01 Cortech, Inc. Bradykinin antagonists
DE4132159A1 (de) * 1991-09-27 1993-04-01 Boehringer Ingelheim Kg 14-hydroxy-n-(2-methoxyethyl)-7,8-dihydromorphin und -norisomorphin, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6004577A (en) * 1997-08-12 1999-12-21 Murdock; Thomas O. Enhanced electrotransport of therapeutic agents having polybasic anionic counter ions
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100619612B1 (ko) * 1999-10-04 2006-09-01 넥타르 테라퓨틱스 에이엘, 코포레이션 폴리머 안정화 신경펩타이드
US20050233459A1 (en) * 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20070258894A1 (en) * 2000-11-08 2007-11-08 Melker Richard J System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring
US20020106331A1 (en) * 2000-12-08 2002-08-08 Joan Rosell Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
KR20040014544A (ko) * 2001-06-05 2004-02-14 컨트롤 딜리버리 시스템즈 인코포레이티드 서방 진통제 화합물
US7338939B2 (en) * 2003-09-30 2008-03-04 New River Pharmaceuticals Inc. Abuse-resistant hydrocodone compounds
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
ATE358275T1 (de) * 2001-11-16 2007-04-15 Randox Lab Ltd Verfahren und kit zum nachweis, oder zum quantifizieren von, metaboliten von fentanyl und metaboliten von fentanyl analoga
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
JP2006520392A (ja) * 2003-03-13 2006-09-07 コントロールド・ケミカルズ・インコーポレーテッド 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP2905033B1 (en) * 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
KR20070011469A (ko) * 2004-04-13 2007-01-24 알자 코포레이션 펜타닐계 약제의 경피전달용 장치 및 방법
EP1790637B1 (en) * 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US20070083186A1 (en) * 2005-09-30 2007-04-12 Darrick Carter Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles
KR101421747B1 (ko) * 2006-04-21 2014-07-30 넥타르 테라퓨틱스 모르피논의 입체선택적 환원
CA2653741C (en) * 2006-05-26 2015-07-07 Thomas E. Jenkins Controlled release of phenolic opioids
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
ES2549115T3 (es) * 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
US8779090B2 (en) * 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
CA2679479C (en) * 2007-03-12 2015-10-06 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8173666B2 (en) * 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US8685979B2 (en) * 2008-01-25 2014-04-01 Nektar Therapeutics Oligomer-diarylpiperazine conjugates
EP2254561A2 (en) * 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
WO2009151590A2 (en) * 2008-06-09 2009-12-17 Nektar Therapeutics Methods of treating cyp2d6 alternative metabolizers
US20100016365A1 (en) * 2008-07-17 2010-01-21 Auspex Pharmaceuticals, Inc. Substituted 4-amino-piperidines
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107019803A (zh) * 2016-01-29 2017-08-08 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
WO2017129046A1 (zh) * 2016-01-29 2017-08-03 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107033154A (zh) * 2016-02-02 2017-08-11 苏州派格生物科技有限公司 阿片受体拮抗剂缀合物及其应用
US11311533B2 (en) 2016-02-02 2022-04-26 Shanghai Hanmai Bio-Pharma Co., Ltd. Opioid receptor antagonist conjugate and use thereof
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
WO2018113581A1 (zh) * 2016-12-22 2018-06-28 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
CN108210933A (zh) * 2016-12-22 2018-06-29 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
CN111107849A (zh) * 2017-07-20 2020-05-05 苏州润鑫达泰生物医药有限公司 抗滥用长效释放阿片样前药
CN111107849B (zh) * 2017-07-20 2024-03-29 苏州润鑫达泰生物医药有限公司 抗滥用长效释放阿片样前药
CN115181109A (zh) * 2021-04-02 2022-10-14 南京正大天晴制药有限公司 吗啡喃衍生物的晶体及其制备方法
CN115181109B (zh) * 2021-04-02 2024-06-04 南京正大天晴制药有限公司 吗啡喃衍生物的晶体及其制备方法

Also Published As

Publication number Publication date
KR20110058783A (ko) 2011-06-01
IL211762A0 (en) 2011-06-30
JP5827123B2 (ja) 2015-12-02
EP3342427A1 (en) 2018-07-04
WO2010033195A1 (en) 2010-03-25
KR101660996B1 (ko) 2016-09-28
AU2009292631A1 (en) 2010-03-25
US20160243111A1 (en) 2016-08-25
MX2011002748A (es) 2011-04-21
JP2012502904A (ja) 2012-02-02
MX347741B (es) 2017-05-10
IL211762A (en) 2016-06-30
EP2340044A1 (en) 2011-07-06
CA2734333A1 (en) 2010-03-25
US20110237614A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
CN102159249A (zh) 具有低滥用潜在性的聚乙二醇化阿片样物质
US10143690B2 (en) Oligomer-opioid agonist conjugates
KR101788886B1 (ko) 올리고머-오피오이드 효능제 컨주게이트
US10512644B2 (en) Oligomer-opioid agonist conjugates
HK1156849A (en) Pegylated opioids with low potential for abuse

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156849

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110817

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1156849

Country of ref document: HK